available of cases in respect of overcharging the prices of bulk drugs and formulations which came to the notice of the Government after promulgation of DPCO, 1987 upto 15th February, 1992 were given in the Statement annexed to reply to Rajya Sabha Unstarred Question No. 418 answered on 27th February, 1992. Thereafter some general complaints of overcharging of the prices of bulk drugs Tri-cqpy to concerned State Drug Controllers. After receipt of replies appropriate action would bg taken as per the due process of law. The liability of overcharging has been worked out only in few cases, as some companies are yet to submit complete data to the Government and in other cases the examinatios and processing is at different stages.

Review of Drug Policy

379. SHRIMATI SATYA BAHIN:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1175 given in Rajya Sabha on 5-3-92

(a) whether the review of Drug Policy after three to five years has resulted in hiding onvmissions and commissions of concenned officials;

(b) whether it is a fact 'that in the guise of review neither the recommendations of the Kelkar Committee accepted earlier have been implemented nor any thing is going to come out of it;

(c) whether it is a fact that total imports by drug companies are neither being monitored nor they arc being used while granting industrial licences;

(d) whether it is a fact that due to this imports have gone up and domestic production has declined;

(e) whether Government propose to appoint any Committee of Members of Parliament to make study of all these issues; and

(f) if so, what are the details thereof and if not, what and the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FER TILIZERS (SHRI CHINTA MOHAN): (a) The review of Drug Policy is necessiated by the changes that take place over the years in the industrial and economic situation. The present review is yet to be complete.

(b) No, Sir. The recommendations of the Kelkar Committee, as accepted by the Government, are incorporated *m* Drugs (Price Control) Order, 1987 and currently prices are fixed under the said Order.

(c) and (d) Industial ilicences are granted keeping in view various factors such as the provisions of the Drug and Industrial' Policies, policy on location etc. The production e* bulk drugs and formulations have registered overall increase every year. Simultansocsly, there has been an incraase in the imports also.

(c) No, Sir.

(f) Doe* not arise.

Unreasonable price increase of medicines

380. SHRI H HANUMANTHAPPA: Will the PRIME'MINISTER be pleased to defer to the answer to Unstarred Question 398 given in the Rajya Sabha on the 26th March. 1992 and state:

(a) what are the basis of determining of the price increase or MAPE charged on price decoptcalled formulation is unreasonable:

(b) what *it the* percentage of price increase or percantage of MAPE over ex-factory cost which invites action from his Ministry;

(c) what are the reasons for which the system *has* been made personalised and arbitrary particularly when the manufacturers are no* submitting data;

(d) what are the reasons for which the limits of MAPE or price increase are not made public to make the system esponsive; and

(e) what was the total number of companies which submitted break up to his